Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. According to the company ...

The Huminsulin range is indicated for type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. | Photo Credit: vitapix Drugmaker Lupin Ltd has acquired ...

Lupin Ltd has announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio for an unspecified amount. Lupin has been marketing the ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30. Lupin had been ...

Lupin Ltd., a global pharmaceutical company, announced on December 30, the acquisition of the Huminsulin range of products in India from Eli Lilly and Company. The financial terms of the deal were ...

The multinational pharmaceutical company had previously used distribution and promotion agreements with Eli Lilly to market the Huminsulin line of products. Indian pharma giant Lupin's shares ...

Lupin acquires Huminsulin brand from Eli Lilly of India to progress in its portfolio in diabetes care. Lupin was already selling Huminsulin under the license agreement entered with Lilly India.

These generic granules are equivalent to Vertex Pharmaceuticals' 'Kalydeco' oral granules in the same strengths.

Stocks like Rail Vikas Nigam, CESC, Dhanlaxmi Bank, Jubilant Ingrevia, Adani Green Energy, Archean Chemical Industries, Century Enka, Bank of India, Prataap Snacks, Power Grid Corporation of India, ...

Lupin announced the acquisition of Huminsulin in India from Eli Lilly and Company. This move aims to significantly strengthen Lupin’s existing diabetes portfolio. Lupin has been marketing the ...